February 1, 2022

Early evidence indicates that iterative detection, profiling, and targeting of minimal residual disease could improve outcomes and even lead to a cure.

Research is ongoing to combat key resistance mechanisms, with new data recently presented by Sara A. Hurvitz, MD, FACP, and other oncologists and investigators during the 2021 San Antonio Breast Cancer Symposium.